Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

Live Evaluations

Topical Therapies in Acne: Why the Mechanism of Action (MOA) Matters In Practice Decisions

About

Topical Therapies in Acne: Why the Mechanism of Action (MOA) Matters In Practice Decisions

This activity is supported by an educational grant from SUN Pharma.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Summarize the pathophysiology of acne and relevant targets for newly available therapies.

  • Define the role of newly available topical therapies for treatment of acne.

  • Identify patients who would benefit from newly available topical acne treatments.

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Hilary
Hilary Baldwin, MD

Director, Acne Treatment and Research Center
Rutgers Robert Wood Johnson Medical Center
New Brunswick, NJ

James
James Del Rosso, DO

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Hilary E. Baldwin, MD

Advisory Board: Bausch, Galderma, Almirall, SUN, La Roche Posay, Cutera 

Consultant: Bausch, Galderma. Almirall, Sun, Cutera 

Speakers’ Bureau or Honoraria: Bausch, Galderma, Almirall, SUN, La Roche Posay

James Q. Del Rosso, DO

Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne

Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne

Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved